About the JPMA

The Japan Pharmaceutical Manufacturers Association (JPMA) is an organization comprising 68 research- and development-oriented pharmaceutical companies (as of October 1, 2026).Since its founding in 1968, guided by the philosophy of “realizing patient-centered healthcare,” the association has contributed to the advancement of global healthcare through the research and development of innovative prescription drugs.In 2026, the association transitioned to a general incorporated association. Taking this as a new step forward, it is addressing the changing social landscape and the environment surrounding drug discovery, and is working to strengthen Japan’s drug discovery capabilities and ensure the early delivery of innovative medicines to patients through co-creation with a wide range of stakeholders.

In recent years, drug discovery has become an increasingly complex and sophisticated endeavor due to the diversification of medical needs and the accelerating pace of technological innovation in the life sciences. To address these changes, the JPMA is working to build and strengthen a drug discovery ecosystem through collaboration among industry, academia, and government.At the same time, we are focusing our efforts on resolving challenges common to the pharmaceutical industry and promoting public understanding of pharmaceuticals. These activities are carried out primarily through committees and specialized organizations that include participants from beyond our member companies, thereby deepening our policy and regulatory advocacy as well as our dialogue with society.

Internationally, as one of the leading pharmaceutical associations alongside the Pharmaceutical Research and Manufacturers of America(PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), we are working to establish international regulations as a founding regulatory member of The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Furthermore, through our leadership of the Asia Pharmaceutical Association Council (APAC), we are contributing to improving access to medicines in the Asian region.Furthermore, as a member organization of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), we address various global health issues, including improving access to medicines, protecting intellectual property, combating infectious diseases, and promoting the Sustainable Development Goals (SDGs).

Going forward, we will further deepen our collaboration with relevant organizations and diverse stakeholders both in Japan and abroad to enhance the transparency and credibility of the entire Japanese pharmaceutical industry and ensure its continued sound development.Furthermore, through “co-creation”—a process of creating value together with the public, including patients—we will drive innovation and contribute to improving the health and quality of life (QOL) of people around the world.

JPMA Guide

Related Information

TOP